Men treated with BEACOPP for Hodgkin lymphoma may be at increased risk of testosterone deficiency

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 963 KB, PDF-dokument

In the current study, we report the prevalence of male testosterone deficiency in a cohort of 60 male long-term survivors of malignant lymphoma with normal total testosterone but in the lower part of the reference level. Testosterone deficiency was defined as subnormal concentrations of total testosterone or subnormal concentrations of calculated free testosterone. The aim was to clarify whether total testosterone was sufficient for identification of testosterone deficiency in male survivors of malignant lymphoma. Hormonal analyses taken at follow-up were compared with samples taken at diagnosis for a subgroup of 20 survivors, for evaluation of changes in hormones over time. Another group of 83 similar survivors of malignant lymphoma with testosterone in the high end of reference levels were also used for comparison, to identify groups of increased risk of testosterone deficiency. A total group of 143 survivors were therefore included in the study. Our findings indicate that for screening purposes an initial total testosterone is sufficient in some survivors because sexual hormone binding globulin concentration was found stable over time. However, 15% were found with subnormal calculated free testosterone. Survivors intensely treated for Hodgkin lymphoma and older survivors were identified as high-risk groups for testosterone deficiency necessitating endocrinological attention during follow-up. Some evidence of pituitary downregulation was also found, because of uncompensated decreases in testosterone concentration over time. In conclusion, longitudinal measurements of total testosterone alone do not seem adequate for the screening of testosterone deficiency for all long-term lymphoma survivors.
TidsskriftAnnals of Hematology
Udgave nummer1
Sider (fra-til)227-239
Antal sider13
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
Open access funding provided by Royal Library, Copenhagen University Library Funding for salary was obtained from the research fund of Department of Hematology, Copenhagen University Hospital—Rigshospitalet; funding for analyses was provided by the Department of Growth and Reproduction, Copenhagen University Hospital—Rigshospitalet, Einar Willumsens Scholarship, Jens and Maren Thestrups Scholarship, and Johannes Fog Fund.

Funding Information:
The work in this article has been made possible by the help provided by Trine Holm Johannsen (biochemical analyses) and Lærke Priskorn (statistics) from the Department of Growth and Reproduction at Copenhagen University Hospital. Furthermore, without the participating patients we would not have been able to perform the studies.

Publisher Copyright:
© 2023, The Author(s).

ID: 382383762